Log In
BCIQ
Print this Print this
 

AV-203

  Manage Alerts
Collapse Summary General Information
Company Aveo Pharmaceuticals Inc.
DescriptionErb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)-targeted antibody
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerCanbridge Life Sciences Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/24/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today